Ardelyx Announces FDA Acceptance for Filing of its New Drug Application of Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis

Author's Avatar
Sep 15, 2020
Article's Main Image

NDA Supported by Data from Expansive Clinical Development Program Demonstrating Tenapanor's use as Foundational Therapy

PDUFA Goal Date - April 29, 2021

PR Newswire